As part of genetic testing, the transmembrane protease serine 2 and erythroblastosis virus E26 oncogene homolog (TMPRSS2:ERG) gene fusion has been studied as a PCa-specific biomarker since 2005 (8, 9). This evidence concerns the gene ERG and posterior cortical atrophy.